ClinicalTrials.gg
RecruitingNCT06399523Updated May 3, 2024

A Study to Evaluate the Efficacy of VR for Bipolar Disorder

An interventional study of VR therapy and VR sham in Bipolar Disorder, VR and Interventional Study, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Bipolar Disorder by Shanghai Mental Health Center — 7 open to participants now, 7 under way, none of them phase 3. Bipolar Disorder · Shanghai Mental Health Center.

Started
2024
with 3 others
No phase
4 of 16
2 open now
Registered
11th of 16
by date

Among the 16 studies in Bipolar Disorder by Shanghai Mental Health Center, this one is one of 4 that started in 2024, is one of 4 with no phase, and was the 11th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

7 of the 16 studies in Bipolar Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Bipolar Disorder by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Bipolar disorder is characterized by high morbidity, recurrence, disability, suicide and comorbidity rate which need novel, efficient, and safe treatment methods, and VR has demonstrate its efficacy in mental disease but not few focus on bipolar disorder. A prospective single center randomize clinical study therefore would be carried on to evaluate the efficacy of VR for Bipolar Disorder in China.

Read the detailed description

Bipolar disorder (BD) refers to a type of mood disorder that clinically manifests as both manic or hypomanic episodes and depressive episodes. Bipolar disorder is characterized by high morbidity, recurrence, disability, suicide and comorbidity rate. The first episode often occurs before age 20, with a lifetime morbidity rate ranging from 1.5% to 6.4% . Patients with bipolar disorder spend significantly more time experiencing depressive episodes than manic or mixed symptoms throughout their lives. At the same time, depressive episodes can cause severe psycho-social disabilities, imposing a heavy economic burden on their families and society .

Despite being the first-line recommended treatment for bipolar depression, pharmacotherapy still cannot fully meet the clinical needs. Some patients do not achieve clinical remission even after receiving adequate and full-course pharmacotherapy. Even if clinical remission is achieved, many patients still have residual symptoms, and those in the maintenance phase still face a high risk of relapse. Psychotherapy has been reported to have various benefits such as improving interpersonal communication skills, enhancing cohesion, and building social support systems, and it has been widely used in the treatment of depression. Although psychological intervention plays a crucial role in the treatment of bipolar depression, its application in reality is still limited. One important reason is the shortage of psychological treatment service resources.

The application of virtual reality (VR) technology in the treatment of mental illnesses has overcome the limitations of traditional psychotherapy techniques. It provides a safer, more controllable, and personalized treatment approach, enabling patients to experience environments and events more intuitively and vividly. This study aims to explore the clinical intervention effects of a mental disorder adjuvant treatment software developed by Nanjing XR-Oasis Technology Co., Ltd. on patients with bipolar disorder experiencing depressive episodes. The technology is based on the theoretical frameworks of cognitive behavioral therapy, interpersonal therapy, mental health education, and Naikan therapy, combined with VR technology.

03

Conditions studied

  • Bipolar Disorder
  • VR
  • Interventional Study

Browse trials for

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 13 years or older
  • Meet the diagnostic criteria for bipolar disorder - depressive episode in the , Fifth Edition (DSM-5)
  • Able to understand the content of the scale
  • Certain abilities in expressive, reading, and listening
  • Total score of >17 on the Hamilton Rating Scale for Depression (HAMD-17)
  • Inform consent

Exclusion criteria

Exclusion Criteria:

  • Poor physical condition unable to participate in the study
  • Currently or previously diagnosed with other major mental disorders according to the , Fifth Edition(DSM-5)
  • Severe or active physical illnesses that interfere with the study treatment
  • Suicidal or self-harming ideas (defined as a score of >3 on item 3 of the Hamilton Depression Scale-17 suicide scale)
  • Pregnant or lactating women
  • Participate in other clinical trials within 1 month
  • Epilepsy or severe eye diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    VR therapy

    Device: VR therapy

  • Placebo comparator
    VR sham

    Device: VR sham

Interventions

  • DeviceVR therapy

    Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.

  • DeviceVR sham

    Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.

06

What researchers measure

Primary outcomes

  1. Evolution of Depression

    Changes in the total score of HAMD-17 at the end of the study compared to baseline

    Time frame: 1 month

Secondary outcomes

  1. Early Response

    A reduction of ≥20% in the total score of HAMD-17 at the end of the 2nd week of treatment compared to baseline

    Time frame: 2 weeks

  2. Clinical Response

    A reduction of ≥50% in the total score of HAMD-17 compared to baseline; specifically, sustained response is defined as a continuous reduction of ≥50% in the total score of HAMD-17 at the end of the 4th and 8th weeks of treatment compared to baseline

    Time frame: 2 months

  3. Clinical Remission

    A total score of HAMD-17 ≤7; particularly, complete remission is defined as a total score of HAMD-17 ≤7 at the end of both the 4th and 8th weeks of treatment

    Time frame: 2 months

  4. Changes in the Clinical Global Impression Scale

    Improvement (CGI-I) and Severity (CGI-S) scores compared to baseline

    Time frame: 2 months

  5. Conversion to mania

    Change of A Young Mania Rating Scale(YMRS) \>13 before and after treatment, and 1 month follow-up

    Time frame: 2 months

  6. Changes in Patient Satisfaction Scale

    Changes in patients satisfaction scale before and after treatment, and 1 month follow-up

    Time frame: 2 months

  7. Change in biological rhythms

    Change in Biological Rhythms Interview of Assessment in Neuropsychiatry(BRAIN) Scale before and after treatment, and 1 month follow-up

    Time frame: 2 months

  8. Change in Quality of life

    Change in quality of life score before and after treatment, and 1 month follow-up

    Time frame: 2 months

  9. Intervention Acceptability

    Acceptability was assessed by questions, "Rate the VR storyline on a scale of 0 to 5". Acceptability was measured with total score of the scale

    Time frame: 2 months

  10. Adverse Events

    Change of Treatment Emergent Symptom Scale(TESS)before and after treatment, and 1 month follow-up

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The prescription data will not be shared with the public. However, if the intervention is effective, the educational materials will be released to the public.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2024, 9 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 9 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
May 3, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Dec 30, 2024
CompletionEst.
Mar 4, 2025
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06399523
Collaborators
Nanjing XR-Oasis Technology Co., Ltd.
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Mar 4, 2024
Primary completion
Dec 30, 2024 (estimated)
Completion
Mar 4, 2025 (estimated)
Last update
May 3, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion